GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Shiller PE Ratio

Biocept (Biocept) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biocept Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocept Shiller PE Ratio Historical Data

The historical data trend for Biocept's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Shiller PE Ratio Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biocept's Shiller PE Ratio

For the Diagnostics & Research subindustry, Biocept's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biocept's Shiller PE Ratio falls into.



Biocept Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biocept's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Biocept's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-3.5/128.7287*128.7287
=-3.500

Current CPI (Jun. 2023) = 128.7287.

Biocept Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -17,126.900 98.790 -22,317.275
201312 -14,802.400 98.326 -19,379.367
201403 -31,267.500 99.695 -40,373.588
201406 -18,273.400 100.560 -23,392.231
201409 -23,535.300 100.428 -30,167.629
201412 -23,667.900 99.070 -30,753.480
201503 -5,741.280 99.621 -7,418.785
201506 -5,847.980 100.684 -7,476.894
201509 -6,469.340 100.392 -8,295.421
201512 -6,342.720 99.792 -8,181.887
201603 -6,588.110 100.470 -8,441.082
201606 -4,972.050 101.688 -6,294.203
201609 -5,083.680 101.861 -6,424.593
201612 -2,430.020 101.863 -3,070.931
201703 -1,890.020 102.862 -2,365.299
201706 -1,896.000 103.349 -2,361.604
201709 -1,770.000 104.136 -2,188.011
201712 -1,620.020 104.011 -2,005.008
201803 -999.000 105.290 -1,221.394
201806 -810.000 106.317 -980.750
201809 -726.000 106.507 -877.476
201812 -429.000 105.998 -520.997
201903 -183.000 107.251 -219.648
201906 -114.000 108.070 -135.793
201909 -74.100 108.329 -88.054
201912 -60.000 108.420 -71.239
202003 -31.800 108.902 -37.590
202006 -15.300 108.767 -18.108
202009 -11.100 109.815 -13.012
202012 4.200 109.897 4.920
202103 5.700 111.754 6.566
202106 -4.200 114.631 -4.717
202109 -1.200 115.734 -1.335
202112 -5.400 117.630 -5.910
202203 -3.900 121.301 -4.139
202206 -17.820 125.017 -18.349
202209 -18.000 125.227 -18.503
202212 -17.100 125.222 -17.579
202303 -12.300 127.348 -12.433
202306 -3.500 128.729 -3.500

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biocept  (OTCPK:BIOCQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biocept Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biocept's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121